MEN Syndromes & Hereditary Endocrine Tumors
MEN1, MEN2A/2B, and the imaging/theranostic implications of hereditary endocrine tumors
Quick Answer
The multiple endocrine neoplasia (MEN) syndromes are autosomal-dominant disorders that cluster endocrine tumors — each with distinct genetics and nuclear-medicine implications. MEN1 (menin gene) = the "3 Ps": parathyroid hyperplasia, pituitary adenoma, and pancreatic/GEP neuroendocrine tumors. MEN2 (RET) centers on medullary thyroid carcinoma (MTC) with pheochromocytoma — plus parathyroid disease (2A) or mucosal neuromas/marfanoid habitus (2B). Recognizing the syndrome drives tracer choice, screening, and prophylactic surgery.
Why It Matters to Nuclear Medicine
Hereditary syndromes change the pretest probability, multiplicity, and biology of endocrine tumors — and therefore imaging strategy. MEN1 patients need SSTR (DOTATATE) imaging for pancreatic NETs and parathyroid localization; MEN2 patients need MTC work-up (calcitonin, FDOPA/DOTATATE/FDG) and genotype-appropriate pheochromocytoma imaging; and germline status enables family screening and prophylactic thyroidectomy.
MEN1 — the "3 Ps" (menin, chromosome 11q13)
| Component | Tumor | Nuclear-medicine relevance |
|---|---|---|
| Parathyroid | Hyperplasia (primary hyperparathyroidism — earliest/most common) | Sestamibi / ¹⁸F-fluorocholine localization (often multiglandular) |
| Pituitary | Adenoma (e.g. prolactinoma) | MRI-based; not typically nuclear |
| Pancreatic/GEP | Gastrinoma (ZES), insulinoma, non-functioning NET | DOTATATE imaging; PRRT for progressive SSTR-avid disease |
Parathyroid disease is usually multiglandular hyperplasia (not a single adenoma), a distinction from sporadic disease.
MEN2 (RET proto-oncogene)
| Feature | MEN2A | MEN2B |
|---|---|---|
| Medullary thyroid carcinoma | Yes (nearly all) | Yes (earlier, more aggressive) |
| Pheochromocytoma | ~50% | ~50% |
| Parathyroid | Hyperparathyroidism | Absent |
| Other | (cutaneous lichen amyloidosis, Hirschsprung in some) | Mucosal neuromas, marfanoid habitus, intestinal ganglioneuromatosis |
RET codon predicts aggressiveness and the timing of prophylactic thyroidectomy (earliest in the highest-risk MEN2B codon M918T). MTC is non-iodine-avid (no NIS) — imaged by FDOPA, DOTATATE, and FDG (see MTC page).
Related Hereditary Tumor Syndromes
- von Hippel–Lindau (VHL): pheochromocytoma/paraganglioma, pancreatic NET/cysts, renal cell carcinoma, hemangioblastoma, retinal angioma.
- NF1: pheochromocytoma, GIST, MPNST.
- SDHx (paraganglioma syndromes): the pseudohypoxia cluster favoring DOTATATE/FDG over MIBG (see pheo/para page).
Imaging & Theranostic Implications (Summary)
- Pancreatic/GEP NET (MEN1): Ga-68-DOTATATE staging + ¹⁷⁷Lu-DOTATATE PRRT for progressive SSTR-avid disease.
- Parathyroid (MEN1/2A): sestamibi / ¹⁸F-fluorocholine — anticipate multiglandular disease.
- MTC (MEN2): calcitonin/CEA doubling times; FDOPA (best localizer), DOTATATE, FDG (aggressive); RET-inhibitor therapy (selpercatinib).
- Pheochromocytoma (MEN2/VHL/NF1): genotype-driven — MEN2 is typically adrenergic (MIBG/FDOPA-avid); confirm MIBG avidity before I-131-MIBG therapy.
Common Pitfalls
- Treating MEN1 parathyroid disease as a single adenoma — it is usually multiglandular hyperplasia.
- Attempting a radioiodine pathway for MTC — C cells lack NIS (a recurring trap).
- Missing a coexisting pheochromocytoma before thyroid/parathyroid surgery in MEN2 (operate on the pheo first).
- Forgetting germline testing/family screening implications when a syndromic tumor is found young or multifocal.
Board Pearls
MEN1 = the "3 Ps" (parathyroid hyperplasia, pituitary adenoma, pancreatic/GEP NET — gastrinoma/insulinoma) via the menin gene; MEN2 (RET) centers on MTC + pheochromocytoma, with parathyroid disease in 2A and mucosal neuromas/marfanoid habitus in 2B.
Syndrome drives tracer choice: DOTATATE (+ PRRT) for MEN1 pancreatic NETs; sestamibi/fluorocholine for (often multiglandular) parathyroid disease; FDOPA/DOTATATE/FDG for MTC (non-iodine-avid); genotype-appropriate imaging for pheochromocytoma (confirm MIBG avidity before I-131-MIBG).
RET codon predicts MTC aggressiveness and prophylactic-thyroidectomy timing (earliest in MEN2B/M918T). In MEN2, operate on a coexisting pheochromocytoma first (α-then-β blockade) to avoid intraoperative crisis. Finding a syndromic endocrine tumor young or multifocal should trigger germline testing and family screening — the nuclear-medicine study is often the first clue.
Related Pages
- Diseases: Medullary thyroid carcinoma, adrenal & pheochromocytoma, neuroendocrine tumors, parathyroid imaging.
- Therapies: ¹⁷⁷Lu-DOTATATE (PRRT), I-131-MIBG; tracer: DOTATATE, I-123-MIBG, sestamibi.
Figure / Diagram Suggestions
- A MEN1 vs MEN2A vs MEN2B feature/gene comparison plate.
- A syndrome → tracer decision map (DOTATATE / sestamibi / FDOPA / MIBG).
- A RET codon → thyroidectomy timing risk ladder.
Self-Check (Board-Style)
Q1. What are the "3 Ps" of MEN1, and which is usually earliest?
Answer: Parathyroid hyperplasia (usually earliest/most common), pituitary adenoma, and pancreatic/GEP neuroendocrine tumors (gene: menin).
Q2. Which imaging is used for MTC in MEN2, and why not radioiodine?
Answer: FDOPA (best localizer), DOTATATE, and FDG; radioiodine fails because C cells lack the sodium-iodide symporter.
Q3. A MEN2A patient needs thyroidectomy but also has a pheochromocytoma. What is the surgical sequencing rule?
Answer: Treat the pheochromocytoma first (α-then-β blockade) to avoid an intraoperative hypertensive crisis.
Q4. How does MEN1 parathyroid disease differ from sporadic primary hyperparathyroidism on imaging?
Answer: It is usually multiglandular hyperplasia rather than a single adenoma — anticipate multiple abnormal glands (sestamibi/fluorocholine may be less clear-cut).
Evidence & sources
https://nuc.med/men-syndromes/ Report an issue